Tricuspid Regurgitation in Ostium Secundum Atrial Septal Defects: Repair or Not?
Keywords:Tricuspid regurgitation, ostium secundum atrial septal defects, repair
Background: Longstanding ostium secundum atrial septal defects lead to functional tricuspid regurgitation. Significant functional tricuspid regurgitation associated with left heart valve disease is addressed at the time of primary left heart valve surgery. In contrast, there is no global recommendation for tricuspid regurgitation associated with atrial septal defects. This study assesses changes in tricuspid regurgitation after isolated atrial septal defect closure.
Methods: Retrospectively, records were examined of 100 patients who underwent isolated ostium secundum atrial septal defect closure without tricuspid valve repair. Echocardiograms were done preoperatively and 3 days, 3 months, and 1 year after surgery. Data on tricuspid regurgitation status, right ventricle dimensions, and pulmonary artery hypertension status were collected and analyzed.
Results: After surgical closure, echocardiography showed a regression of tricuspid regurgitation to mild or less in 76% of patients at 3 days, 89% at 3 months, and 93% at 1 year. Severe pulmonary artery hypertension (32% patients preoperatively) showed statistically significant regression: 14% at 3 days, 10% at 3 months, and 2% at 1 year. Preoperatively, the mean right ventricular internal diameter was 37.9 mm, which decreased to 34 ± 5.5 mm (mean ± standard deviation) at 3 days, 32.3 ± 5.3 mm at 3 months, and 31.3 ± 5.4 mm at 1 year. It was also noted that regression favored patients who were <25 years old.
Conclusion: Tricuspid valve repair may not be required in patients with ostium secundum atrial septal defect with functional tricuspid regurgitation.
Baumgartner H, Falk V, Bax JJ, et al. 2017. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38:2739-2791.
Berbarie RF, Anwar A, Dockery WD, et al. 2007. Measurement of right ventricular volumes before and after atrial septal defect closure using multi slice CT. Am J Cardiol 99:1458-1461.
Dehghani H, Boyle AJ. 2012. Percutaneous device closure of secundum atrial septal defect in older adults. Am J Cardiovasc Dis 2:133-142.
Gatzoulis MA, Rodington AN, Somerville J et al. 1996. Should atrial septal defects in adults be closed? Ann Thorac Surg 61:657-659.
Ghosh S, Chatterjee S, Black E, Firmin RK. 2002. Surgical closure of atrial septal defects in adults: Effect of age at operation on outcome. Heart 88:485-487.
Hamer JPM. 1990. Practical Echocardiography in the Adult. Springer Netherlands, Dordrecht. 238 pp.
Hoashi T, Yazaki S, Kagisaki K, et al. 2015. Management of ostium secundum atrial septal defect in the era of percutaneous trans-catheter device closure: 7-Year experience at a single institution. J Cardiol 65:418-422.
Humenberger M Rosenhek R, Gabriel H, et al. 2011. Benefits of atrial septal defect closure in adults: Impact of age. Eur Heart J 32:553-560.
Jemielity M, Dyszkiewicz W, Paluszkiewicz L, et al. 2001. Do patients over 40 years of age benefit from surgical closure of atrial septal defects? Heart 85:300-303.
Kotowycz MA, Therrien J, Ionescu-Ittu R, et al. 2013. Long-term outcomes after surgical versus transcatheter closure of atrial septal defects in adults. JACC Cardiovasc Interv 6:497-503.
Krovetz LJ. Normal standards for cardiovascular data. II. Pressure and vascular resistances. 1972. John Hopkins Med J 130:187-195.
Lang RM, Bierig M, Devereux RB, et al. 2005. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Eur J Echocardiogr 7:79-108.
Levin AR, Levin AR, Spach MS, et al. 1968. Atrial pressure-flow dynamics in atrial septal defects (secundum type). Circulation 37:476-488.
Liberthson RR, Boucher CA, Strauss HW, Dinsmore RE, McKusick KA, Pohost GM. 1981. Right ventricular function in adult atrial septal defect: Preoperative and postoperative assessment and clinical implications. Am J Cardiol 47:56-60.
Maatouk F, Ben Farhat M, Betbout F, et al. 2001. Right ventricular dilatation and intraventricular septal motion after surgical closure of atrial septal defect. Arch Mal Coeur Vaiss 94:204-210.
Mohanan Nair KK, Pillai HS, Thajudeen A, et al. 2012. Immediate and long-term results following balloon mitral valvotomy in patients with atrial fibrillation. Clin Cardiol 35:35-39.
Moodie D, Sterba R. 2000. Long term outcomes excellent for atrial septal defect repair in adults. Cleve Clin J Med 67:657.
Nishimura RA, Otto CM, Bonow RO, et al. 2014. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:2440-2492.
Oakley C. 1996. Closure of atrial septal defects in adult life. Cardiologia 41:31.
Rao PS, Harris AD. 2017. Recent advances in managing septal defects: Atrial septal defects. F1000Res 6:2042.
Rosas M, Attie F, Sandoval J, et al. 2004. Atrial septal defects in adults ≥40 years old: Negative impact of low arterial saturation. Int J Cardiol 93:145-155.
Webb G, Gatzolius MA. 2006. Atrial septal defects in the adult: Recent progress and overview. Circulation 114:1645-1653.
Weyman AE. 1994. Principles and Practice of Echocardiography, Second Edition. Lippincott Williams & Wilkins; Philadelphia. 1335 pp.
Zoghbi WA, Enriquez-Sarano M, Foster E, et al. 2003. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777-802.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).